retatrutide retatrutide Lilly's Retatrutide: Toward the End of Incremental Metabolic Medicine Demand for Unapproved Weight-Loss Drug

Keywords: drug-induced thyroiditis, glp-1 receptor agonist, hypothyroidism, thyroid dysfunction, tirzepatide Introduction Dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, including tirzepatide, are increasingly prescribed for type 2 diabetes and obesity due to their efficacy in glycemic control and weight reduction

Yet glucagon also has broader metabolic actions

Most weight loss occurs in the first 24 to 36 weeks, with maintenance thereafter

In TRIUMPH-4, the 12mg group had higher rates of dysesthesia (20.9% vs

The maximum impact occurs after about 30 weeks of treatment

What to expect during the transition The first 1 to 2 weeks after switching may feel different from your injectable experience even at equivalent doses